LKT Laboratories, Inc.

BEZ235

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B1996
CAS No. 915019-65-7
Chemical Name

Synonym NVP-BEZ235, Dactolisib

Formula $C_{30}H_{23}N_5O$
Formula Wt. 469.54
Melting Point
Purity ≥98%
Solubility

DMF	18 mg/mL warmed (38.33 mM)
DMSO	0.01 mg/mL (0.02 mM)
Water	Insoluble



Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
B1996	10 mg	$60.60
B1996	25 mg	$130.20
B1996	100 mg	$390.70

Store Temp -20°C
Ship Temp Ambient

Description BEZ235 inhibits PI3K and mTORC1/2, exhibiting anticancer chemotherapeutic activity. In nasopharyngeal cancer cells, BEZ235 induces G1 phase cell cycle arrest and apoptosis; in similar animal models of nasopharyngeal or cholangiocarcinoma, this compound inhibits tumor growth. BEZ235 also induces apoptosis in hepatocellular carcinoma cells, also potentially inducing autophagy.

References

Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.

Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34 (6):3637-48. PMID: 23832540.

Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.